Evidence map›Paper›PMID 40667242›Full record

ArticlebioRxiv : the preprint server for biology2025

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models.

Peyton C High, Zhengdong Liang, Cara Guernsey-Biddle, Shraddha Subramanian, Yueh-Ming Shyu, Adela M Aldana, Yukimatsu Toh, Kendra S Carmon

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Peyton C HighCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Zhengdong LiangCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Cara Guernsey-BiddleCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Shraddha SubramanianCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Yueh-Ming ShyuCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Adela M AldanaCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Yukimatsu TohCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Kendra S CarmonCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.ORCID 0000-0002-3244-6096

Funding

Mechanisms and therapeutic targeting of colon cancer stem cell plasticityR01CA226894 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CARMON, KENDRA S. · 2018 to 2022
$1.8M
Training Interdisciplinary Pharmacology Scientists (TIPS)T32GM139801 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Carmen W. Dessauer · 2021 to 2026
$1.5M
Novel Antibody-Drug Conjugate Combination Therapy for Treating Colorectal CancerR21CA270716 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CARMON, KENDRA S. · 2022 to 2023
$397k
Bispecific drug-conjugates for treating colorectal cancerR21CA282378 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CARMON, KENDRA S. · 2024 to 2025
$394k
NCI NIH HHS R01 CA226894NCI NIH HHS R21 CA270716NCI NIH HHS R21 CA282378NIGMS NIH HHS T32 GM139801
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains the second-leading cause of cancer-associated deaths, indicating an urgent need for improved therapeutic options. We previously generated antibody-drug conjugates (ADCs) targeting the cancer stem-like cell marker leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). However, tumor relapse due to LGR5 downregulation and suboptimal payload selection warranted strategies to improve ADC efficacy. Here we report cetuximab, an EGFR-targeting monoclonal antibody indicated for

Indexed as

Antibody-drug conjugatecetuximabcolorectal cancercombination treatmentEGFRLGR5

Identifiers

PMID40667242
PMCPMC12262463

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.